{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:59:20Z","timestamp":1783958360155,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1093\/rheumatology\/kel030","type":"journal-article","created":{"date-parts":[[2006,2,4]],"date-time":"2006-02-04T01:48:35Z","timestamp":1139017715000},"page":"982-989","source":"Crossref","is-referenced-by-count":168,"title":["Tumour necrosis factor \u03b1 inhibitors in the treatment of childhood uveitis"],"prefix":"10.1093","volume":"45","author":[{"given":"R. K.","family":"Saurenmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rabinovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Laxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,2,3]]},"reference":[{"key":"key\n\t\t\t\t20171012062142_BIB1","doi-asserted-by":"crossref","unstructured":"Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol2003;135:676\u201380.","DOI":"10.1016\/S0002-9394(02)02148-7"},{"key":"key\n\t\t\t\t20171012062142_BIB2","doi-asserted-by":"crossref","unstructured":"Paivonsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand2000;78:84\u20138.","DOI":"10.1034\/j.1600-0420.2000.078001084.x"},{"key":"key\n\t\t\t\t20171012062142_BIB3","doi-asserted-by":"crossref","unstructured":"Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology2004;111:491\u2013500.","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"key\n\t\t\t\t20171012062142_BIB4","doi-asserted-by":"crossref","unstructured":"Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing patterns in uveitis of childhood. Ophthalmology1996;103:375\u201383.","DOI":"10.1016\/S0161-6420(96)30682-9"},{"key":"key\n\t\t\t\t20171012062142_BIB5","doi-asserted-by":"crossref","unstructured":"Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm2000;8:251\u201361.","DOI":"10.1076\/ocii.8.4.251.6459"},{"key":"key\n\t\t\t\t20171012062142_BIB6","doi-asserted-by":"crossref","unstructured":"Stoffel PB, Sauvain MJ, von Vigier RO, Beretta-Piccoli BC, Ramelli GP, Bianchetti MG. Non-infectious causes of uveitis in 70 Swiss children. Acta Paediatr2000;89:955\u20138.","DOI":"10.1111\/j.1651-2227.2000.tb00416.x"},{"key":"key\n\t\t\t\t20171012062142_BIB7","doi-asserted-by":"crossref","unstructured":"Kadayifcilar S, Eldem B, Tumer B. Uveitis in childhood. J Pediatr Ophthalmol Strabismus2003;40:335\u201340.","DOI":"10.3928\/0191-3913-20031101-06"},{"key":"key\n\t\t\t\t20171012062142_BIB8","doi-asserted-by":"crossref","unstructured":"Smith JR. Management of uveitis in pediatric patients: special considerations. Paediatr Drugs2002;4:183\u20139.","DOI":"10.2165\/00128072-200204030-00005"},{"key":"key\n\t\t\t\t20171012062142_BIB9","doi-asserted-by":"crossref","unstructured":"Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol2003;135:867\u201378.","DOI":"10.1016\/S0002-9394(03)00314-3"},{"key":"key\n\t\t\t\t20171012062142_BIB10","doi-asserted-by":"crossref","unstructured":"Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol1998;82:737\u201342.","DOI":"10.1136\/bjo.82.7.737"},{"key":"key\n\t\t\t\t20171012062142_BIB11","doi-asserted-by":"crossref","unstructured":"Hesselink DA, Baarsma GS, Kuijpers RW, van Hagen PM. Experience with cyclosporine in endogenous uveitis posterior. Transplant Proc2004;36:372S\u2013377S.","DOI":"10.1016\/j.transproceed.2004.01.003"},{"key":"key\n\t\t\t\t20171012062142_BIB12","doi-asserted-by":"crossref","unstructured":"Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr1998;133:266\u20138.","DOI":"10.1016\/S0022-3476(98)70232-X"},{"key":"key\n\t\t\t\t20171012062142_BIB13","doi-asserted-by":"crossref","unstructured":"Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology2001;108:1134\u20139.","DOI":"10.1016\/S0161-6420(01)00576-0"},{"key":"key\n\t\t\t\t20171012062142_BIB14","doi-asserted-by":"crossref","unstructured":"Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology2003;110:1061\u20135.","DOI":"10.1016\/S0161-6420(03)00092-7"},{"key":"key\n\t\t\t\t20171012062142_BIB15","doi-asserted-by":"crossref","unstructured":"Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol2003;31:487\u201391.","DOI":"10.1046\/j.1442-9071.2003.00704.x"},{"key":"key\n\t\t\t\t20171012062142_BIB16","doi-asserted-by":"crossref","unstructured":"Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology2004;111:960\u20135.","DOI":"10.1016\/j.ophtha.2003.08.034"},{"key":"key\n\t\t\t\t20171012062142_BIB17","doi-asserted-by":"crossref","unstructured":"Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology2002;109:137\u201342.","DOI":"10.1016\/S0161-6420(01)00864-8"},{"key":"key\n\t\t\t\t20171012062142_BIB18","doi-asserted-by":"crossref","unstructured":"Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs2004;6:137\u201346.","DOI":"10.2165\/00148581-200406030-00001"},{"key":"key\n\t\t\t\t20171012062142_BIB19","doi-asserted-by":"crossref","unstructured":"Reiff A, Takei S, Sadeghi S et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum2001;44:1411\u20135.","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O"},{"key":"key\n\t\t\t\t20171012062142_BIB20","doi-asserted-by":"crossref","unstructured":"Smith JR, Levinson RD, Holland GN et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum2001;45:252\u20137.","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5"},{"key":"key\n\t\t\t\t20171012062142_BIB21","doi-asserted-by":"crossref","unstructured":"Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol2003;87:925.","DOI":"10.1136\/bjo.87.7.925"},{"key":"key\n\t\t\t\t20171012062142_BIB22","doi-asserted-by":"crossref","unstructured":"De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res1995;61:667\u201375.","DOI":"10.1016\/S0014-4835(05)80017-X"},{"key":"key\n\t\t\t\t20171012062142_BIB23","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology2001;121:1088\u201394.","DOI":"10.1053\/gast.2001.28674"},{"key":"key\n\t\t\t\t20171012062142_BIB24","doi-asserted-by":"crossref","unstructured":"Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev2004:CD003574.","DOI":"10.1002\/14651858.CD003574.pub2"},{"key":"key\n\t\t\t\t20171012062142_BIB25","doi-asserted-by":"crossref","unstructured":"Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology2001;121:1145\u201357.","DOI":"10.1053\/gast.2001.28702"},{"key":"key\n\t\t\t\t20171012062142_BIB26","doi-asserted-by":"crossref","unstructured":"ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut2002;50:206\u201311.","DOI":"10.1136\/gut.50.2.206"},{"key":"key\n\t\t\t\t20171012062142_BIB27","unstructured":"Sartani G, Silver PB, Rizzo LV et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci1996;37:2211\u20138."},{"key":"key\n\t\t\t\t20171012062142_BIB28","doi-asserted-by":"crossref","unstructured":"Santos Lacomba M, Marcos Martin C et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res2001;33:251\u20135.","DOI":"10.1159\/000055677"},{"key":"key\n\t\t\t\t20171012062142_BIB29","unstructured":"Kasner L, Chan CC, Whitcup SM, Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci1993;34:2911\u20137."},{"key":"key\n\t\t\t\t20171012062142_BIB30","doi-asserted-by":"crossref","unstructured":"Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum2005;53:18\u201323.","DOI":"10.1002\/art.20904"},{"key":"key\n\t\t\t\t20171012062142_BIB31","doi-asserted-by":"crossref","unstructured":"Foster CS, Tufail F, Waheed NK et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol2003;121:437\u201340.","DOI":"10.1001\/archopht.121.4.437"},{"key":"key\n\t\t\t\t20171012062142_BIB32","doi-asserted-by":"crossref","unstructured":"Mangge H, Heinzl B, Grubbauer HM, El-Shabrawi Y, Schauenstein K. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int2003;23:258\u201361.","DOI":"10.1007\/s00296-003-0308-1"},{"key":"key\n\t\t\t\t20171012062142_BIB33","doi-asserted-by":"crossref","unstructured":"Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology2004;111:352\u20136.","DOI":"10.1016\/S0161-6420(03)00721-8"},{"key":"key\n\t\t\t\t20171012062142_BIB34","doi-asserted-by":"crossref","unstructured":"Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol2005;33:461\u20138.","DOI":"10.1111\/j.1442-9071.2005.01062.x"},{"key":"key\n\t\t\t\t20171012062142_BIB35","doi-asserted-by":"crossref","unstructured":"El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology2002;109:2342\u20136.","DOI":"10.1016\/S0161-6420(02)01292-7"},{"key":"key\n\t\t\t\t20171012062142_BIB36","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med2004;140:404\u20136.","DOI":"10.7326\/0003-4819-140-5-200403020-00025"},{"key":"key\n\t\t\t\t20171012062142_BIB37","doi-asserted-by":"crossref","unstructured":"Suhler EB, Smith JR, Wertheim MS et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol2005;123:903\u201312.","DOI":"10.1001\/archopht.123.7.903"},{"key":"key\n\t\t\t\t20171012062142_BIB38","doi-asserted-by":"crossref","unstructured":"Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol2004;138:648\u201350.","DOI":"10.1016\/j.ajo.2004.04.066"},{"key":"key\n\t\t\t\t20171012062142_BIB39","doi-asserted-by":"crossref","unstructured":"Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology2004;111:2299\u2013306.","DOI":"10.1016\/j.ophtha.2004.06.014"},{"key":"key\n\t\t\t\t20171012062142_BIB40","doi-asserted-by":"crossref","unstructured":"Foster CS, Havrlikova K, Baltatzis S, Christen WG, Merayo-Lloves J. Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Acta Ophthalmol Scand2000;78:576\u20139.","DOI":"10.1034\/j.1600-0420.2000.078005576.x"},{"key":"key\n\t\t\t\t20171012062142_BIB41","doi-asserted-by":"crossref","unstructured":"Freedman SF, Rodriguez-Rosa RE, Rojas MC, Enyedi LB. Goniotomy for glaucoma secondary to chronic childhood uveitis. Am J Ophthalmol2002;133:617\u201321.","DOI":"10.1016\/S0002-9394(02)01344-2"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/45\/8\/982\/9448113\/kel030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:38:35Z","timestamp":1555439915000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/rheumatology\/article\/45\/8\/982\/2899425\/Tumour-necrosis-factor-\u03b1-inhibitors-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,3]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,2,3]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kel030","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,8]]},"published":{"date-parts":[[2006,2,3]]}}}